Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients - Takeaways - MDSpire

Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients

  • By

  • Makoto Hibino

  • Ayumi Shintani

  • Hiroyuki Murayama

  • Nobuyuki Morikawa

  • Kazunari Maeda

  • Sho Nishiguchi

  • Eiji Monma

  • Hiromasa Harada

  • Tsunekazu Takagi

  • Satoshi Kuroyanagi

  • Kiyoshi Endo

  • Yasushi Terada

  • Masahiro Kinoshita

  • Takahiro Yoden

  • Shogo Miyazawa

  • Shinichi Higashiue

  • May 15, 2026

  • 0 min

Share

  • 1

    Post–COVID-19 condition (PCC) significantly contributes to long-term morbidity, characterized by persistent symptoms like fatigue and respiratory complaints.

  • 2

    Early antiviral treatment may reduce the risk of PCC by limiting viral replication and subsequent inflammation in COVID-19 patients.

  • 3

    The ANCHOR study evaluated the association between early oral antiviral use and PCC risk among outpatients in Japan during the Omicron era.

  • 4

    Eligible participants included outpatients aged 12 or older with symptomatic COVID-19 and no prior anti–SARS-CoV-2 treatment in the last 30 days.

  • 5

    The primary outcome was the proportion of participants developing PCC, defined by persistent symptoms reported at both 28 and 84 days post-enrollment.

Original Source(s)

Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients

  • by Makoto Hibino, Ayumi Shintani, Hiroyuki Murayama, Nobuyuki Morikawa, Kazunari Maeda, Sho Nishiguchi, Eiji Monma, Hiromasa Harada, Tsunekazu Takagi, Satoshi Kuroyanagi, Kiyoshi Endo, Yasushi Terada, Masahiro Kinoshita, Takahiro Yoden, Shogo Miyazawa, Shinichi Higashiue

  • May 15, 2026

Related Content

Clinical characteristics and antibody responses to Omicron variants among pregnant women in China during the December 2022–April 2023 COVID-19 pandemic wave

Acute liver failure and secondary TMA-like phenomenon following SARS-CoV-2 and Mycoplasma pneumoniae co-detection in a child: a case report

Multi-omics analysis of long COVID (post-COVID-19 condition) reveals persistent mitochondrial dysfunction, suppressed oxidative phosphorylation, and immune dysregulation